<DOC>
	<DOCNO>NCT01246063</DOCNO>
	<brief_summary>The aim phase I/II trial determine maximal tolerate dose ( MTD ) carfilzomib together pegylated liposomal doxorubicin hydrochloride ( PLD ) without dexamethasone , establish efficacy safety novel combination patient relapse refractory multiple myeloma</brief_summary>
	<brief_title>Carfilzomib , Pegylated Liposomal Doxorubicin Hydrochloride , Dexamethasone Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>Phase I dose-escalation study . Patients receive carfilzomib intravenously ( IV ) Days 1 , 2 , 8 , 9 , 15 , 16 Cycles 1-6 , Days 1 , 8 , 15 , 22 begin Cycle 7 disease progression relapse . Participants treat prior approval Amendment 1 carfilzomib administer Days 1 , 2 , 8 , 9 , 15 , 16 Cycles 1 2 Days 1 , 8 , 15 , 22 begin Cycle 3 . PLD administered Day 8 Cycles 1-6 . Dexamethasone administer schedule carfilzomib ( patient treat part 2 phase 1 phase 2 ) . Cycles repeat every 28 day absence disease progression unacceptable toxicity . Phase II use MTD Phase I .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically confirm diagnosis multiple myeloma measurable disease parameter time screen ; measurable disease parameter define one following : Serum monoclonal protein &gt; = 0.5 g/dl 24 hour urine monoclonal protein &gt; = 0.2 g/24 hour Serum free light chain ratio &gt; 5 x normal ratio absolute difference 10mg/dl involve uninvolved free light chain Soft tissue plasmacytoma &gt; = 2 cm measurable either physical examination and/or applicable radiograph ( e.g . magnetic resonance image [ MRI ] , compute tomography [ CT ] , etc ) Bone Marrow Plasma Cells &gt; = 30 % Documentation least one line prior myeloma therapy relapse refractory disease require retreatment At least 18 year age time sign informed consent . Performance status Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 Karnofsky &gt; = 60 % ; participant low performance status base solely bone pain secondary multiple myeloma eligible Required laboratory value Alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) &lt; 2.5 x upper limit institutional normal value ( ULN ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Absolute neutrophil count ( ANC ) &gt; = 1,000 Hemoglobin &gt; = 8 g/dl Platelets &gt; = 50,000 Creatinine clearance &gt; 15 ml/minute use CockcroftGault formula For participant receive warfarin ( Coumadin ) , unfractionated heparin , lowmolecular weight heparin therapy , applicable coagulation parameter monitor must within accept therapeutic range indication Transfusions and/or growth factor dependent participant exclude parameter achieve support Females childbearing potential ( FCBP ) must agree refrain become pregnant study drug 3 month discontinuation study drug , must agree use adequate contraception include hormonal contraception , ( i.e . birth control pill , etc ) , barrier method contraception ( i.e . condom ) , abstinence time frame ; FCBP must agree regular pregnancy test timeframe ; inclusion FCBP require two negative pregnancy test prior enrollment . All woman , regardless age , consider FCBP unless surgically sterile ( post hysterectomy , post bilateral oophorectomy , etc ) naturally post menopausal &gt; = 24 consecutive month Men engage sexual intercourse FCBP must agree use adequate contraception include hormonal contraception , ( i.e . birth control pill , etc ) , barrier method contraception ( i.e . condom ) , abstinence study drug 3 month discontinuation study drug Ability understand willing sign write informed consent document POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Plasma Cell Leukemia Waldenstrom 's macroglobulinemia Pregnant lactating female Use antimyeloma drug therapy within 14 day initiation study drug treatment exclude corticosteroid give indication myeloma ; bisphosphonates consider antimyeloma drug Participation investigational therapeutic study within 14 day initiation study drug treatment Radiotherapy multiple site immunotherapy within 14 day initiation study drug treatment ( localized radiotherapy single site least 7 day start permissible ) Major surgery within 14 day initiation study drug treatment Participants require program oral ( PO ) IV fluid hydration contraindicate Prior history hypersensitivity reaction PLD , doxorubicin , bortezomib , carfilzomib , liposomal drug formulation PLD ; history reaction liposomal drug formulation PLD evaluate individually reaction felt due encapsulate agent , rather liposomal component exclude discretion investigator Participants know active hepatitis A , B , C viral infection may participate study ; active disease define participant know viral hepatitis whose liver function test elevate Known human immunodeficiency virus ( HIV ) seropositive take antiretrovirals may participate study ; participant HIVseropositive antiretroviral therapy otherwise meet inclusion/exclusion criterion eligible study Compromised cardiovascular function define follow : Electrocardiogram ( EKG ) evidence acute ischemia EKG evidence medically significant conduction system abnormalities History myocardial infarction within last 6 month Unstable angina pectoris cardiac arrhythmia History Class 3 Class 4 New York Heart Association Congestive Heart Failure within 6 month enrollment study Left ventricular ejection fraction ( LVEF ) &lt; 45 % either echocardiography radionuclidebased multiple gated acquisition ( Echo MUGA ) Uncontrolled concurrent illness include : hematologic nonhematologic malignancy , active infection , uncontrolled diabetes Any significant psychological , medical , surgical condition think compromise participant , study , prevent inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>